Format

Send to

Choose Destination
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8379-84. doi: 10.1073/pnas.1501443112. Epub 2015 Jun 22.

Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial.

Author information

1
Division of Experimental Medicine, University of California, San Francisco, CA 94110; peter.kuebler@ucsf.edu.
2
Institute of Virology & Immunology, Gladstone Institutes, San Francisco, CA 94158;
3
Division of Experimental Medicine, University of California, San Francisco, CA 94110;
4
Division of Clinical Immunology and Allergy, University of São Paulo, São Paulo, Brazil 01246;
5
Division of Experimental Medicine, University of California, San Francisco, CA 94110; Department of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, DC 20037;
6
Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94158;
7
Institute of Virology & Immunology, Gladstone Institutes, San Francisco, CA 94158; Department of Medicine, University of California, San Francisco, CA 94143.

Abstract

HIV-1-specific T-cell responses in exposed seronegative subjects suggest that a viral breach of the exposure site is more common than current transmission rates would suggest and that host immunity can extinguish subsequent infection foci. The Preexposure Prophylaxis Initiative (iPrEx) chemoprophylaxis trial provided an opportunity to rigorously investigate these responses in a case-control immunology study; 84 preinfection peripheral blood mononuclear cell samples from individuals enrolled in the iPrEx trial who later seroconverted were matched with 480 samples from enrolled subjects who remained seronegative from both the placebo and active treatment arms. T-cell responses to HIV-1 Gag, Protease, Integrase, Reverse Transcriptase, Vif, and Nef antigens were quantified for all subjects in an IFN-γ enzyme-linked immunospot (ELISpot) assay. IFN-γ responses varied in magnitude and frequency across subjects. A positive response was more prevalent in those who remained persistently HIV-1-negative for Gag (P = 0.007), Integrase (P < 0.001), Vif (P < 0.001), and Nef (P < 0.001). When correlated with outcomes in the iPrEx trial, Vif- and Integrase-specific T-cell responses were associated with reduced HIV-1 infection risk [hazard ratio (HR) = 0.36, 95% confidence interval (95% CI) = 0.19-0.66 and HR = 0.52, 95% CI = 0.28-0.96, respectively]. Antigen-specific responses were independent of emtricitabine/tenofovir disoproxil fumarate use. IFN-γ secretion in the ELISpot was confirmed using multiparametric flow cytometry and largely attributed to effector memory CD4+ or CD8+ T cells. Our results show that HIV-1-specific T-cell immunity can be detected in exposed but uninfected individuals and that these T-cell responses can differentiate individuals according to infection outcomes.

KEYWORDS:

HIV-1; T cell; designated HIV-1–exposed seronegative; preexposure chemoprophylaxis; vaccine

PMID:
26100867
PMCID:
PMC4500209
DOI:
10.1073/pnas.1501443112
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center